Yuan Chen

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.1K citations

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pharmacology +6

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 662 citations · Full text

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pathology +6

Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy

Tina Cascone, Jodi A. McKenzie, Rina M. Mbofung et al. · Cell Metabolism · 2018 · 600 citations · Full text

Tumor Immunology, Cancer Immunosurveillance, T-regulatory Cell +12

NLRP3 Phosphorylation Is an Essential Priming Event for Inflammasome Activation

Nan Song, Zhao-Shan Liu, Wen Xue et al. · Molecular Cell · 2017 · 473 citations · Full text

Inflammation, Signal Transduction, Signaling Pathway +10

Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis

Yuan Chen, Thomas Knösel, Glen Kristiansen et al. · The Journal of Pathology · 2003 · 262 citations

Medicine, Tumour Progression, Immunology +12